About Us

Peptides sit between small molecules and proteins in size and complexity. With the right chemistry — cyclization, non-natural amino acids, methylation — they can match the potency and selectivity of antibodies while keeping the drug-like properties of small molecules. Peptides are no longer a niche modality: Blockbusters like Ozempic anchor a $72-billion-and-growing market, peptides now account for more than 8% of FDA approvals, and roughly 13% of Americans have tried one. Yet navigating the effectively infinite chemical space of non-natural peptides remains a fundamental challenge.

We are building a self-driving laboratory (SDL) for peptide drug discovery — an AI-directed loop where each round of wet-lab experiments generates data that improves the next round of model-driven design. We rely on direct-to-biology methods, particularly affinity-selection mass spectrometry (AS-MS), to evaluate molecules without purification and feed results immediately back to the models that design the next experiment.

Read more about the research areas that make this possible, meet the team behind it, or learn about the PI.

The Lab

Contact Us

Sponsors and Collaborators